| Name | Title | Contact Details |
|---|---|---|
Valarie A |
Chief People Officer | Profile |
Valarie Arismendez |
Chief People Officer | Profile |
Valarie Arismendez |
Senior Vice President People | Profile |
Paul Neuman |
Senior Director of Sales Development | Profile |
Lolita Amica |
Vice President Of Global Talent | Profile |
Amsino International is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Conductive Technologies is a York, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ATLAS Lift Tech is transforming the way care delivery organizations nationwide deploy and manage safe patient handling and mobility (SPHM) programs.
One of every nine Americans is a member of an Anthem, Inc. affiliated health plan. For us, that`s a tremendous privilege and responsibility. Our focus every day is on improving the lives of the people we serve and the health of our communities. The foundation of our work can be summarized by: Delivering consistent service and becoming faster and simpler with every action we take. Creating the best health care value for our customers Investing where returns are the greatest to make the best use of our current assets. Being a market leader in each of our chosen businesses. Continuing to advocate for responsible health care reform.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.